Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Net Income (2016 - 2025)

Historic Net Income for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$27.9 million.

  • Voyager Therapeutics' Net Income fell 20840.34% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 58988.41%. This contributed to the annual value of -$65.0 million for FY2024, which is 14912.11% down from last year.
  • Voyager Therapeutics' Net Income amounted to -$27.9 million in Q3 2025, which was down 20840.34% from -$33.4 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Net Income registered a high of $124.0 million during Q1 2023, and its lowest value of -$34.5 million during Q4 2024.
  • Over the past 5 years, Voyager Therapeutics' median Net Income value was -$22.2 million (recorded in 2023), while the average stood at -$7.7 million.
  • Per our database at Business Quant, Voyager Therapeutics' Net Income tumbled by 56669.3% in 2022 and then surged by 68184.72% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Net Income stood at $5.1 million in 2021, then crashed by 566.69% to -$23.6 million in 2022, then surged by 338.86% to $56.4 million in 2023, then tumbled by 161.15% to -$34.5 million in 2024, then grew by 19.12% to -$27.9 million in 2025.
  • Its Net Income was -$27.9 million in Q3 2025, compared to -$33.4 million in Q2 2025 and -$31.0 million in Q1 2025.